Terms ending in 2043
Every in-force patent on Schrödinger, Inc.'s record whose computed term ends in 2043, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,715,876 | Cyclic Compounds and Methods of Using Same In force · High confidence | Schrödinger, Inc. | In force | High confidence | |
| US 12,686,688 | Heterocyclic Pericondensed CDC7 Kinase Inhibitors for the Treatment of Cancer In force · High confidence | Schrödinger, Inc. | In force | High confidence | |
| US 12,667,572 | Tricyclic Compounds Useful in the Treatment of Cancer, Autoimmune and Inflammatory Disorders In force · High confidence | Schrödinger, Inc. | In force | High confidence | |
| US 12,774,274 | Heterocyclic Compounds and Methods of Use In force · High confidence | Schrödinger, Inc. | In force | High confidence |
4 of 4 patents shown. Soonest term end first, then patent number.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.